Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy - Summary - MDSpire

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

Share

Objective:

To evaluate the efficacy and safety of Nivolumab-AVD compared to BV-AVD in treating advanced-stage classical Hodgkin lymphoma (cHL).

Key Findings:
  • Nivolumab-AVD showed a one-year progression-free survival (PFS) rate of 94% compared to 86% for BV-AVD.
  • Neutropenia was more common in the Nivo-AVD group (56%) compared to BV-AVD (34%).
  • Nivolumab-AVD was better tolerated, with lower rates of peripheral sensory neuropathy (29% vs. 56%).
  • Older patients (over 60) had a PFS rate of 93% with Nivo-AVD versus 64% with BV-AVD.
Interpretation:

Nivolumab-AVD demonstrates superior efficacy and a more favorable safety profile compared to BV-AVD in treating advanced-stage cHL, particularly in older patients.

Limitations:
  • The study results are based on interim analyses and require confirmation from larger phase III trials.
  • Long-term toxicity and quality of life outcomes need further investigation.
Conclusion:

Nivolumab-AVD represents a promising treatment option for advanced-stage classical Hodgkin lymphoma, with improved efficacy and tolerability compared to traditional therapies.

Original Source(s)

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

  • by Maria D. Guerrero

  • May 6, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...